428 related articles for article (PubMed ID: 9108425)
1. CD6-depleted allogeneic bone marrow transplantation for acute leukemia in first complete remission.
Soiffer RJ; Fairclough D; Robertson M; Alyea E; Anderson K; Freedman A; Bartlett-Pandite L; Fisher D; Schlossman RL; Stone R; Murray C; Freeman A; Marcus K; Mauch P; Nadler L; Ritz J
Blood; 1997 Apr; 89(8):3039-47. PubMed ID: 9108425
[TBL] [Abstract][Full Text] [Related]
2. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
[TBL] [Abstract][Full Text] [Related]
3. Prevention of graft-versus-host disease by selective depletion of CD6-positive T lymphocytes from donor bone marrow.
Soiffer RJ; Murray C; Mauch P; Anderson KC; Freedman AS; Rabinowe SN; Takvorian T; Robertson MJ; Spector N; Gonin R
J Clin Oncol; 1992 Jul; 10(7):1191-200. PubMed ID: 1607923
[TBL] [Abstract][Full Text] [Related]
4. CD6+ T cell-depleted allogeneic bone marrow transplantation for non-Hodgkin's lymphoma.
Soiffer RJ; Freedman AS; Neuberg D; Fisher DC; Alyea EP; Gribben J; Schlossman RL; Bartlett-Pandite L; Kuhlman C; Murray C; Freeman A; Mauch P; Anderson KC; Nadler LM; Ritz J
Bone Marrow Transplant; 1998 Jun; 21(12):1177-81. PubMed ID: 9674848
[TBL] [Abstract][Full Text] [Related]
5. CD6+ donor marrow T-cell depletion as the sole form of graft-versus-host disease prophylaxis in patients undergoing allogeneic bone marrow transplant from unrelated donors.
Soiffer RJ; Weller E; Alyea EP; Mauch P; Webb IL; Fisher DC; Freedman AS; Schlossman RL; Gribben J; Lee S; Anderson KC; Marcus K; Stone RM; Antin JH; Ritz J
J Clin Oncol; 2001 Feb; 19(4):1152-9. PubMed ID: 11181681
[TBL] [Abstract][Full Text] [Related]
6. T-cell--depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect.
Alyea E; Weller E; Schlossman R; Canning C; Webb I; Doss D; Mauch P; Marcus K; Fisher D; Freeman A; Parikh B; Gribben J; Soiffer R; Ritz J; Anderson K
Blood; 2001 Aug; 98(4):934-9. PubMed ID: 11493435
[TBL] [Abstract][Full Text] [Related]
7. Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant.
Alyea EP; Soiffer RJ; Canning C; Neuberg D; Schlossman R; Pickett C; Collins H; Wang Y; Anderson KC; Ritz J
Blood; 1998 May; 91(10):3671-80. PubMed ID: 9573003
[TBL] [Abstract][Full Text] [Related]
8. T-cell depletion plus salvage immunotherapy with donor leukocyte infusions as a strategy to treat chronic-phase chronic myelogenous leukemia patients undergoing HLA-identical sibling marrow transplantation.
Drobyski WR; Hessner MJ; Klein JP; Kabler-Babbitt C; Vesole DH; Margolis DA; Keever-Taylor CA
Blood; 1999 Jul; 94(2):434-41. PubMed ID: 10397710
[TBL] [Abstract][Full Text] [Related]
9. A new marrow T cell depletion method using anti-CD6 monoclonal antibody-conjugated magnetic beads and its clinical application for prevention of acute graft-vs.-host disease in allogeneic bone marrow transplantation: results of a phase I-II trial.
Sao H; Kitaori K; Kasai M; Shimokawa T; Kato C; Yamanishi H; Ueda R; Morishima Y
Int J Hematol; 1999 Jan; 69(1):27-35. PubMed ID: 10641440
[TBL] [Abstract][Full Text] [Related]
10. Prediction of graft-versus-host disease by phenotypic analysis of early immune reconstitution after CD6-depleted allogeneic bone marrow transplantation.
Soiffer RJ; Gonin R; Murray C; Robertson MJ; Cochran K; Chartier S; Cameron C; Daley J; Levine H; Nadler LM
Blood; 1993 Oct; 82(7):2216-23. PubMed ID: 7691252
[TBL] [Abstract][Full Text] [Related]
11. Allogeneic bone marrow transplantation for leukemia with marrow grafts depleted of lymphocytes by counterflow centrifugation.
Schattenberg A; De Witte T; Preijers F; Raemaekers J; Muus P; Van der Lely N; Boezeman J; Wessels J; Van Dijk B; Hoogenhout J
Blood; 1990 Mar; 75(6):1356-63. PubMed ID: 2310832
[TBL] [Abstract][Full Text] [Related]
12. T-cell-depleted allogeneic bone marrow transplantation as postremission therapy for acute myelogenous leukemia: freedom from relapse in the absence of graft-versus-host disease.
Papadopoulos EB; Carabasi MH; Castro-Malaspina H; Childs BH; Mackinnon S; Boulad F; Gillio AP; Kernan NA; Small TN; Szabolcs P; Taylor J; Yahalom J; Collins NH; Bleau SA; Black PM; Heller G; O'Reilly RJ; Young JW
Blood; 1998 Feb; 91(3):1083-90. PubMed ID: 9446672
[TBL] [Abstract][Full Text] [Related]
13. Bone marrow transplantation for children less than 2 years of age with acute myelogenous leukemia or myelodysplastic syndrome.
Woolfrey AE; Gooley TA; Sievers EL; Milner LA; Andrews RG; Walters M; Hoffmeister P; Hansen JA; Anasetti C; Bryant E; Appelbaum FR; Sanders JE
Blood; 1998 Nov; 92(10):3546-56. PubMed ID: 9808546
[TBL] [Abstract][Full Text] [Related]
14. Donor T-lymphocyte infusion for unrelated allogeneic bone marrow transplantation with CD3+ T-cell-depleted graft.
Lee CK; deMagalhaes-Silverman M; Hohl RJ; Hayashi M; Buatti J; Wen BC; Schlueter A; Strauss RG; Gingrich RD
Bone Marrow Transplant; 2003 Jan; 31(2):121-8. PubMed ID: 12621494
[TBL] [Abstract][Full Text] [Related]
15. Allogeneic bone marrow transplantation for leukemia with marrow grafts treated by counterflow centrifugation.
De Witte T; Schattenberg A; Preijers F; Raymakers R; Muus P; Wessels J
Bone Marrow Transplant; 1993; 12 Suppl 3():S2-6. PubMed ID: 8124252
[TBL] [Abstract][Full Text] [Related]
16. Allogeneic cell-mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic bone marrow transplantation for hematological malignancies.
Naparstek E; Nagler A; Or R; Kapelushnik J; Slavin S
Clin Transpl; 1996; ():281-90. PubMed ID: 9286578
[TBL] [Abstract][Full Text] [Related]
17. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W
Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465
[TBL] [Abstract][Full Text] [Related]
18. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft.
Herrera C; Torres A; GarcĂa-Castellano JM; Roman J; Martin C; Serrano J; Falcon M; Alvarez MA; Gomez P; Martinez F
Bone Marrow Transplant; 1999 Mar; 23(5):443-50. PubMed ID: 10100557
[TBL] [Abstract][Full Text] [Related]
19. Reducing transplant-related mortality after allogeneic hematopoietic stem cell transplantation.
Bacigalupo A; Sormani MP; Lamparelli T; Gualandi F; Occhini D; Bregante S; Raiola AM; di Grazia C; Dominietto A; Tedone E; Piaggio G; Podesta M; Bruno B; Oneto R; Lombardi A; Frassoni F; Rolla D; Rollandi G; Viscoli C; Ferro C; Garbarino L; Van Lint MT
Haematologica; 2004 Oct; 89(10):1238-47. PubMed ID: 15477210
[TBL] [Abstract][Full Text] [Related]
20. Selective T cell depletion of donor allogeneic marrow with anti-CD6 monoclonal antibody: rationale and results.
Soiffer RJ; Ritz J
Bone Marrow Transplant; 1993; 12 Suppl 3():S7-10. PubMed ID: 8124262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]